Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects
Status:
Completed
Trial end date:
2014-04-24
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the effect of ethinyl estradiol
(EE)/norgestimate, a weak cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK)
of lomitapide and 2 primary metabolites, M1 and M3.